Sound waves aim to boost heart health in amyloidosis patients

NCT ID NCT04667494

Recruiting now Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special ultrasound treatment, combined with a contrast agent, can improve blood flow and heart function in people with cardiac amyloidosis. Researchers will measure changes using PET scans and echocardiograms. The trial includes 70 participants with and without amyloidosis to see how the therapy affects the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sonotherapy (high mechanical index ultrasound with intravenous Definity contrast)
What this could lead to: If it works, this could point toward a non-invasive way to improve heart blood flow and function in people with cardiac amyloidosis.
What could go wrong: This is a small early pilot study with only 70 participants, so results may not apply widely. The therapy is experimental and risks are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS CARDIAC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Amyloid Neuropathies, Familial wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOIDOSIS CARDIAC

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.